Thursday, September 24, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

View original at finance.yahoo.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma Group plc Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Setrusumab demonstrated statistically significant improvements in bone mineral density and compelling reductions in vertebral fractures

    60% confidence

  • Data from setrusumab studies may provide basis for engagement with regulatory agencies despite missing primary endpoints

    60% confidence

  • Partnering discussions around alvelestat in AATD-LD are continuing to advance on multiple fronts

    60% confidence

  • Revised financial runway into mid-2027 enables potential delivery of several key milestones during 2026

    60% confidence

  • Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab in osteogenesis imperfecta are ongoing

    60% confidence

  • There are no FDA or EMA therapies approved specifically for osteogenesis imperfecta

    60% confidence

  • Single Phase 3 trial enrolling approximately 220 AATD-LD patients will support regulatory submissions in both U.S. and Europe

    60% confidence

  • āshibio plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in the second half of 2026

    60% confidence

  • Existing cash and cash equivalents will enable funding of operations into mid-2027

    60% confidence

  • Phase 3 Orbit and Cosmic studies did not achieve statistical significance on primary endpoints of fracture reduction

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights — Source | Via News | Via News